Shteinfer-Kuzmine A - Search Results

1

Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology.

Verma A, Shteinfer-Kuzmine A, Kamenetsky N, Pittala S, Paul A, Nahon Crystal E, Ouro A, Chalifa-Caspi V, Pandey SK, Monsonego A, Vardi N, Knafo S, Shoshan-Barmatz V. Verma A, et al. Transl Neurodegener. 2022 Dec 28;11(1):58. doi: 10.1186/s40035-022-00329-7. Transl Neurodegener. 2022. PMID: 36578022 Free PMC article.

2

Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction.

Ben-Hail D, Begas-Shvartz R, Shalev M, Shteinfer-Kuzmine A, Gruzman A, Reina S, De Pinto V, Shoshan-Barmatz V. Ben-Hail D, et al. J Biol Chem. 2016 Nov 25;291(48):24986-25003. doi: 10.1074/jbc.M116.744284. Epub 2016 Oct 13. J Biol Chem. 2016. PMID: 27738100 Free PMC article.

3

Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma.

Shteinfer-Kuzmine A, Arif T, Krelin Y, Tripathi SS, Paul A, Shoshan-Barmatz V. Shteinfer-Kuzmine A, et al. Oncotarget. 2017 May 9;8(19):31329-31346. doi: 10.18632/oncotarget.15455. Oncotarget. 2017. PMID: 28412744 Free PMC article.

4

VDAC1 functions in Ca²⁺ homeostasis and cell life and death in health and disease.

Shoshan-Barmatz V, Krelin Y, Shteinfer-Kuzmine A. Shoshan-Barmatz V, et al. Cell Calcium. 2018 Jan;69:81-100. doi: 10.1016/j.ceca.2017.06.007. Epub 2017 Jun 23. Cell Calcium. 2018. PMID: 28712506 Review.

5

Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.

Shoshan-Barmatz V, Krelin Y, Shteinfer-Kuzmine A, Arif T. Shoshan-Barmatz V, et al. Front Oncol. 2017 Jul 31;7:154. doi: 10.3389/fonc.2017.00154. eCollection 2017. Front Oncol. 2017. PMID: 28824871 Free PMC article. Review.

6

VDAC1, mitochondrial dysfunction, and Alzheimer's disease.

Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-Kuzmine A, Gupta R. Shoshan-Barmatz V, et al. Pharmacol Res. 2018 May;131:87-101. doi: 10.1016/j.phrs.2018.03.010. Epub 2018 Mar 15. Pharmacol Res. 2018. PMID: 29551631 Review.

7

Hypoxic-induced truncation of voltage-dependent anion channel 1 is mediated by both asparagine endopeptidase and calpain 1 activities.

Pahima H, Reina S, Tadmor N, Dadon-Klein D, Shteinfer-Kuzmine A, Mazure NM, De Pinto V, Shoshan-Barmatz V. Pahima H, et al. Oncotarget. 2018 Jan 31;9(16):12825-12841. doi: 10.18632/oncotarget.24377. eCollection 2018 Feb 27. Oncotarget. 2018. PMID: 29560113 Free PMC article.

8

Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy.

Shteinfer-Kuzmine A, Amsalem Z, Arif T, Zooravlov A, Shoshan-Barmatz V. Shteinfer-Kuzmine A, et al. Mol Oncol. 2018 Jun;12(7):1077-1103. doi: 10.1002/1878-0261.12313. Epub 2018 May 19. Mol Oncol. 2018. PMID: 29698587 Free PMC article.

9

Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States.

Arif T, Paul A, Krelin Y, Shteinfer-Kuzmine A, Shoshan-Barmatz V. Arif T, et al. Cancers (Basel). 2018 Dec 8;10(12):499. doi: 10.3390/cancers10120499. Cancers (Basel). 2018. PMID: 30544833 Free PMC article.

10

A VDAC1-Derived N-Terminal Peptide Inhibits Mutant SOD1-VDAC1 Interactions and Toxicity in the SOD1 Model of ALS.

Shteinfer-Kuzmine A, Argueti S, Gupta R, Shvil N, Abu-Hamad S, Gropper Y, Hoeber J, Magrì A, Messina A, Kozlova EN, Shoshan-Barmatz V, Israelson A. Shteinfer-Kuzmine A, et al. Front Cell Neurosci. 2019 Aug 14;13:346. doi: 10.3389/fncel.2019.00346. eCollection 2019. Front Cell Neurosci. 2019. PMID: 31474832 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters